Pharma & Healthcare
Global Dupilumab Injection Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 04, 25
- ID: 570425
- Pages: 116
- Figures: 122
- Views: 6
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Dupilumab Injection market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Regeneron
Sanofi
Segment by Type
200mg (1.14mL)/Vial
300mg (2.0 mL)/Vial
Segment by Application
Atopic Dermatitis
Asthma
Chronic Sinusitis with Nasal Polyps
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Dupilumab Injection study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Dupilumab Injection market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Regeneron
Sanofi
Segment by Type
200mg (1.14mL)/Vial
300mg (2.0 mL)/Vial
Segment by Application
Atopic Dermatitis
Asthma
Chronic Sinusitis with Nasal Polyps
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Dupilumab Injection study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Dupilumab Injection: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Dupilumab Injection Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 200mg (1.14mL)/Vial
1.2.3 300mg (2.0 mL)/Vial
1.3 Market Segmentation by Application
1.3.1 Global Dupilumab Injection Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Atopic Dermatitis
1.3.3 Asthma
1.3.4 Chronic Sinusitis with Nasal Polyps
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Dupilumab Injection Revenue Estimates and Forecasts 2020-2031
2.2 Global Dupilumab Injection Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Dupilumab Injection Sales Estimates and Forecasts 2020-2031
2.4 Global Dupilumab Injection Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Dupilumab Injection Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Dupilumab Injection Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 200mg (1.14mL)/Vial Market Size by Manufacturers
3.6 Global Dupilumab Injection Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Dupilumab Injection Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Dupilumab Injection Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Dupilumab Injection Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Dupilumab Injection Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Dupilumab Injection Sales and Revenue by Type (2020-2031)
6.4 North America Dupilumab Injection Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Dupilumab Injection Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Dupilumab Injection Sales and Revenue by Type (2020-2031)
7.4 Europe Dupilumab Injection Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Dupilumab Injection Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Dupilumab Injection Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Dupilumab Injection Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Dupilumab Injection Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Dupilumab Injection Sales and Revenue by Type (2020-2031)
9.4 Central and South America Dupilumab Injection Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Dupilumab Injection Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Dupilumab Injection Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Dupilumab Injection Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Dupilumab Injection Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Regeneron
11.1.1 Regeneron Corporation Information
11.1.2 Regeneron Business Overview
11.1.3 Regeneron Dupilumab Injection Product Models, Descriptions and Specifications
11.1.4 Regeneron Dupilumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Regeneron Dupilumab Injection Sales by Product in 2024
11.1.6 Regeneron Dupilumab Injection Sales by Application in 2024
11.1.7 Regeneron Dupilumab Injection Sales by Geographic Area in 2024
11.1.8 Regeneron Dupilumab Injection SWOT Analysis
11.1.9 Regeneron Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Dupilumab Injection Product Models, Descriptions and Specifications
11.2.4 Sanofi Dupilumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi Dupilumab Injection Sales by Product in 2024
11.2.6 Sanofi Dupilumab Injection Sales by Application in 2024
11.2.7 Sanofi Dupilumab Injection Sales by Geographic Area in 2024
11.2.8 Sanofi Dupilumab Injection SWOT Analysis
11.2.9 Sanofi Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Dupilumab Injection Industry Chain
12.2 Dupilumab Injection Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Dupilumab Injection Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Dupilumab Injection Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Dupilumab Injection Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Dupilumab Injection Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Dupilumab Injection: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Dupilumab Injection Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 200mg (1.14mL)/Vial
1.2.3 300mg (2.0 mL)/Vial
1.3 Market Segmentation by Application
1.3.1 Global Dupilumab Injection Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Atopic Dermatitis
1.3.3 Asthma
1.3.4 Chronic Sinusitis with Nasal Polyps
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Dupilumab Injection Revenue Estimates and Forecasts 2020-2031
2.2 Global Dupilumab Injection Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Dupilumab Injection Sales Estimates and Forecasts 2020-2031
2.4 Global Dupilumab Injection Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Dupilumab Injection Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Dupilumab Injection Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 200mg (1.14mL)/Vial Market Size by Manufacturers
3.6 Global Dupilumab Injection Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Dupilumab Injection Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Dupilumab Injection Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Dupilumab Injection Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Dupilumab Injection Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Dupilumab Injection Sales and Revenue by Type (2020-2031)
6.4 North America Dupilumab Injection Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Dupilumab Injection Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Dupilumab Injection Sales and Revenue by Type (2020-2031)
7.4 Europe Dupilumab Injection Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Dupilumab Injection Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Dupilumab Injection Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Dupilumab Injection Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Dupilumab Injection Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Dupilumab Injection Sales and Revenue by Type (2020-2031)
9.4 Central and South America Dupilumab Injection Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Dupilumab Injection Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Dupilumab Injection Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Dupilumab Injection Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Dupilumab Injection Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Regeneron
11.1.1 Regeneron Corporation Information
11.1.2 Regeneron Business Overview
11.1.3 Regeneron Dupilumab Injection Product Models, Descriptions and Specifications
11.1.4 Regeneron Dupilumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Regeneron Dupilumab Injection Sales by Product in 2024
11.1.6 Regeneron Dupilumab Injection Sales by Application in 2024
11.1.7 Regeneron Dupilumab Injection Sales by Geographic Area in 2024
11.1.8 Regeneron Dupilumab Injection SWOT Analysis
11.1.9 Regeneron Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Dupilumab Injection Product Models, Descriptions and Specifications
11.2.4 Sanofi Dupilumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi Dupilumab Injection Sales by Product in 2024
11.2.6 Sanofi Dupilumab Injection Sales by Application in 2024
11.2.7 Sanofi Dupilumab Injection Sales by Geographic Area in 2024
11.2.8 Sanofi Dupilumab Injection SWOT Analysis
11.2.9 Sanofi Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Dupilumab Injection Industry Chain
12.2 Dupilumab Injection Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Dupilumab Injection Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Dupilumab Injection Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Dupilumab Injection Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Dupilumab Injection Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Dupilumab Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Dupilumab Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Dupilumab Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Dupilumab Injection Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Dupilumab Injection Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Dupilumab Injection Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Dupilumab Injection Sales by Region (2020-2025) & (K Units)
Table 8. Global Dupilumab Injection Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Dupilumab Injection Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Dupilumab Injection Sales Share by Manufacturers (2020-2025)
Table 12. Global Dupilumab Injection Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Dupilumab Injection Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Dupilumab Injection by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dupilumab Injection as of 2024)
Table 16. Global Dupilumab Injection Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Dupilumab Injection Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Dupilumab Injection Manufacturing Base and Headquarters
Table 19. Global Dupilumab Injection Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Dupilumab Injection Sales by Type (2020-2025) & (K Units)
Table 23. Global Dupilumab Injection Sales by Type (2026-2031) & (K Units)
Table 24. Global Dupilumab Injection Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Dupilumab Injection Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Dupilumab Injection ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Dupilumab Injection Sales by Application (2020-2025) & (K Units)
Table 29. Global Dupilumab Injection Sales by Application (2026-2031) & (K Units)
Table 30. Dupilumab Injection High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Dupilumab Injection Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Dupilumab Injection Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Dupilumab Injection ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Dupilumab Injection Growth Accelerators and Market Barriers
Table 37. North America Dupilumab Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Dupilumab Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Dupilumab Injection Growth Accelerators and Market Barriers
Table 40. Europe Dupilumab Injection Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Dupilumab Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Dupilumab Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Dupilumab Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Dupilumab Injection Growth Accelerators and Market Barriers
Table 45. Southeast Asia Dupilumab Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Dupilumab Injection Investment Opportunities and Key Challenges
Table 47. Central and South America Dupilumab Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Dupilumab Injection Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Dupilumab Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Regeneron Corporation Information
Table 51. Regeneron Description and Major Businesses
Table 52. Regeneron Product Models, Descriptions and Specifications
Table 53. Regeneron Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Regeneron Sales Value Proportion by Product in 2024
Table 55. Regeneron Sales Value Proportion by Application in 2024
Table 56. Regeneron Sales Value Proportion by Geographic Area in 2024
Table 57. Regeneron Dupilumab Injection SWOT Analysis
Table 58. Regeneron Recent Developments
Table 59. Sanofi Corporation Information
Table 60. Sanofi Description and Major Businesses
Table 61. Sanofi Product Models, Descriptions and Specifications
Table 62. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Sanofi Sales Value Proportion by Product in 2024
Table 64. Sanofi Sales Value Proportion by Application in 2024
Table 65. Sanofi Sales Value Proportion by Geographic Area in 2024
Table 66. Sanofi Dupilumab Injection SWOT Analysis
Table 67. Sanofi Recent Developments
Table 68. Key Raw Materials Distribution
Table 69. Raw Materials Key Suppliers
Table 70. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 71. Milestones in Production Technology Evolution
Table 72. Distributors List
Table 73. Market Trends and Market Evolution
Table 74. Market Drivers and Opportunities
Table 75. Market Challenges, Risks, and Restraints
Table 76. Research Programs/Design for This Report
Table 77. Key Data Information from Secondary Sources
Table 78. Key Data Information from Primary Sources
List of Figures
Figure 1. Dupilumab Injection Product Picture
Figure 2. Global Dupilumab Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. 200mg (1.14mL)/Vial Product Picture
Figure 4. 300mg (2.0 mL)/Vial Product Picture
Figure 5. Global Dupilumab Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Atopic Dermatitis
Figure 7. Asthma
Figure 8. Chronic Sinusitis with Nasal Polyps
Figure 9. Other
Figure 10. Dupilumab Injection Report Years Considered
Figure 11. Global Dupilumab Injection Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 13. Global Dupilumab Injection Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Dupilumab Injection Revenue Market Share by Region (2020-2031)
Figure 15. Global Dupilumab Injection Sales (2020-2031) & (K Units)
Figure 16. Global Dupilumab Injection Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global Dupilumab Injection Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Dupilumab Injection Sales Volume Market Share in 2024
Figure 19. Global Dupilumab Injection Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. 200mg (1.14mL)/Vial Revenue Market Share by Manufacturer in 2024
Figure 22. 300mg (2.0 mL)/Vial Revenue Market Share by Manufacturer in 2024
Figure 23. Global Dupilumab Injection Sales Market Share by Type (2020-2031)
Figure 24. Global Dupilumab Injection Revenue Market Share by Type (2020-2031)
Figure 25. Global Dupilumab Injection Sales Market Share by Application (2020-2031)
Figure 26. Global Dupilumab Injection Revenue Market Share by Application (2020-2031)
Figure 27. North America Dupilumab Injection Sales YoY (2020-2031) & (K Units)
Figure 28. North America Dupilumab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 29. North America Top 5 Manufacturers Dupilumab Injection Sales Revenue (US$ Million) in 2024
Figure 30. North America Dupilumab Injection Sales Volume (K Units) by Type (2020- 2031)
Figure 31. North America Dupilumab Injection Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 32. North America Dupilumab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 33. North America Dupilumab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 34. US Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 35. Canada Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 36. Mexico Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 37. Europe Dupilumab Injection Sales YoY (2020-2031) & (K Units)
Figure 38. Europe Dupilumab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Europe Top 5 Manufacturers Dupilumab Injection Sales Revenue (US$ Million) in 2024
Figure 40. Europe Dupilumab Injection Sales Volume (K Units) by Type (2020-2031)
Figure 41. Europe Dupilumab Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 42. Europe Dupilumab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 43. Europe Dupilumab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 44. Germany Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 45. France Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 46. U.K. Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 47. Italy Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 48. Russia Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 49. Asia-Pacific Dupilumab Injection Sales YoY (2020-2031) & (K Units)
Figure 50. Asia-Pacific Dupilumab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Asia-Pacific Top 8 Manufacturers Dupilumab Injection Sales Revenue (US$ Million) in 2024
Figure 52. Asia-Pacific Dupilumab Injection Sales Volume (K Units) by Type (2020- 2031)
Figure 53. Asia-Pacific Dupilumab Injection Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 54. Asia-Pacific Dupilumab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 55. Asia-Pacific Dupilumab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 56. Indonesia Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 57. Japan Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 58. South Korea Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 59. China Taiwan Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 60. India Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 61. Central and South America Dupilumab Injection Sales YoY (2020-2031) & (K Units)
Figure 62. Central and South America Dupilumab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Central and South America Top 5 Manufacturers Dupilumab Injection Sales Revenue (US$ Million) in 2024
Figure 64. Central and South America Dupilumab Injection Sales Volume (K Units) by Type (2021-2031)
Figure 65. Central and South America Dupilumab Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 66. Central and South America Dupilumab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 67. Central and South America Dupilumab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 68. Brazil Dupilumab Injection Revenue (2020-2025) & (US$ Million)
Figure 69. Argentina Dupilumab Injection Revenue (2020-2025) & (US$ Million)
Figure 70. Middle East, and Africa Dupilumab Injection Sales YoY (2020-2031) & (K Units)
Figure 71. Middle East and Africa Dupilumab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 72. Middle East and Africa Top 5 Manufacturers Dupilumab Injection Sales Revenue (US$ Million) in 2024
Figure 73. Middle East and Africa Dupilumab Injection Sales Volume (K Units) by Type (2021-2031)
Figure 74. South America Dupilumab Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 75. Middle East and Africa Dupilumab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 76. Middle East and Africa Dupilumab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 77. GCC Countries Dupilumab Injection Revenue (2020-2025) & (US$ Million)
Figure 78. Turkey Dupilumab Injection Revenue (2020-2025) & (US$ Million)
Figure 79. Egypt Dupilumab Injection Revenue (2020-2025) & (US$ Million)
Figure 80. South Africa Dupilumab Injection Revenue (2020-2025) & (US$ Million)
Figure 81. Dupilumab Injection Industry Chain Mapping
Figure 82. Regional Dupilumab Injection Manufacturing Base Distribution (%)
Figure 83. Global Dupilumab Injection Production Market Share by Region (2020-2031)
Figure 84. Dupilumab Injection Production Process
Figure 85. Regional Dupilumab Injection Production Cost Structure
Figure 86. Channels of Distribution (Direct Vs Distribution)
Figure 87. Bottom-up and Top-down Approaches for This Report
Figure 88. Data Triangulation
Figure 89. Key Executives Interviewed
Table 1. Global Dupilumab Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Dupilumab Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Dupilumab Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Dupilumab Injection Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Dupilumab Injection Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Dupilumab Injection Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Dupilumab Injection Sales by Region (2020-2025) & (K Units)
Table 8. Global Dupilumab Injection Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Dupilumab Injection Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Dupilumab Injection Sales Share by Manufacturers (2020-2025)
Table 12. Global Dupilumab Injection Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Dupilumab Injection Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Dupilumab Injection by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dupilumab Injection as of 2024)
Table 16. Global Dupilumab Injection Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Dupilumab Injection Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Dupilumab Injection Manufacturing Base and Headquarters
Table 19. Global Dupilumab Injection Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Dupilumab Injection Sales by Type (2020-2025) & (K Units)
Table 23. Global Dupilumab Injection Sales by Type (2026-2031) & (K Units)
Table 24. Global Dupilumab Injection Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Dupilumab Injection Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Dupilumab Injection ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Dupilumab Injection Sales by Application (2020-2025) & (K Units)
Table 29. Global Dupilumab Injection Sales by Application (2026-2031) & (K Units)
Table 30. Dupilumab Injection High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Dupilumab Injection Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Dupilumab Injection Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Dupilumab Injection ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Dupilumab Injection Growth Accelerators and Market Barriers
Table 37. North America Dupilumab Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Dupilumab Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Dupilumab Injection Growth Accelerators and Market Barriers
Table 40. Europe Dupilumab Injection Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Dupilumab Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Dupilumab Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Dupilumab Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Dupilumab Injection Growth Accelerators and Market Barriers
Table 45. Southeast Asia Dupilumab Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Dupilumab Injection Investment Opportunities and Key Challenges
Table 47. Central and South America Dupilumab Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Dupilumab Injection Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Dupilumab Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Regeneron Corporation Information
Table 51. Regeneron Description and Major Businesses
Table 52. Regeneron Product Models, Descriptions and Specifications
Table 53. Regeneron Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Regeneron Sales Value Proportion by Product in 2024
Table 55. Regeneron Sales Value Proportion by Application in 2024
Table 56. Regeneron Sales Value Proportion by Geographic Area in 2024
Table 57. Regeneron Dupilumab Injection SWOT Analysis
Table 58. Regeneron Recent Developments
Table 59. Sanofi Corporation Information
Table 60. Sanofi Description and Major Businesses
Table 61. Sanofi Product Models, Descriptions and Specifications
Table 62. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Sanofi Sales Value Proportion by Product in 2024
Table 64. Sanofi Sales Value Proportion by Application in 2024
Table 65. Sanofi Sales Value Proportion by Geographic Area in 2024
Table 66. Sanofi Dupilumab Injection SWOT Analysis
Table 67. Sanofi Recent Developments
Table 68. Key Raw Materials Distribution
Table 69. Raw Materials Key Suppliers
Table 70. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 71. Milestones in Production Technology Evolution
Table 72. Distributors List
Table 73. Market Trends and Market Evolution
Table 74. Market Drivers and Opportunities
Table 75. Market Challenges, Risks, and Restraints
Table 76. Research Programs/Design for This Report
Table 77. Key Data Information from Secondary Sources
Table 78. Key Data Information from Primary Sources
List of Figures
Figure 1. Dupilumab Injection Product Picture
Figure 2. Global Dupilumab Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. 200mg (1.14mL)/Vial Product Picture
Figure 4. 300mg (2.0 mL)/Vial Product Picture
Figure 5. Global Dupilumab Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Atopic Dermatitis
Figure 7. Asthma
Figure 8. Chronic Sinusitis with Nasal Polyps
Figure 9. Other
Figure 10. Dupilumab Injection Report Years Considered
Figure 11. Global Dupilumab Injection Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 13. Global Dupilumab Injection Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Dupilumab Injection Revenue Market Share by Region (2020-2031)
Figure 15. Global Dupilumab Injection Sales (2020-2031) & (K Units)
Figure 16. Global Dupilumab Injection Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global Dupilumab Injection Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Dupilumab Injection Sales Volume Market Share in 2024
Figure 19. Global Dupilumab Injection Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. 200mg (1.14mL)/Vial Revenue Market Share by Manufacturer in 2024
Figure 22. 300mg (2.0 mL)/Vial Revenue Market Share by Manufacturer in 2024
Figure 23. Global Dupilumab Injection Sales Market Share by Type (2020-2031)
Figure 24. Global Dupilumab Injection Revenue Market Share by Type (2020-2031)
Figure 25. Global Dupilumab Injection Sales Market Share by Application (2020-2031)
Figure 26. Global Dupilumab Injection Revenue Market Share by Application (2020-2031)
Figure 27. North America Dupilumab Injection Sales YoY (2020-2031) & (K Units)
Figure 28. North America Dupilumab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 29. North America Top 5 Manufacturers Dupilumab Injection Sales Revenue (US$ Million) in 2024
Figure 30. North America Dupilumab Injection Sales Volume (K Units) by Type (2020- 2031)
Figure 31. North America Dupilumab Injection Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 32. North America Dupilumab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 33. North America Dupilumab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 34. US Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 35. Canada Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 36. Mexico Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 37. Europe Dupilumab Injection Sales YoY (2020-2031) & (K Units)
Figure 38. Europe Dupilumab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Europe Top 5 Manufacturers Dupilumab Injection Sales Revenue (US$ Million) in 2024
Figure 40. Europe Dupilumab Injection Sales Volume (K Units) by Type (2020-2031)
Figure 41. Europe Dupilumab Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 42. Europe Dupilumab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 43. Europe Dupilumab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 44. Germany Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 45. France Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 46. U.K. Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 47. Italy Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 48. Russia Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 49. Asia-Pacific Dupilumab Injection Sales YoY (2020-2031) & (K Units)
Figure 50. Asia-Pacific Dupilumab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Asia-Pacific Top 8 Manufacturers Dupilumab Injection Sales Revenue (US$ Million) in 2024
Figure 52. Asia-Pacific Dupilumab Injection Sales Volume (K Units) by Type (2020- 2031)
Figure 53. Asia-Pacific Dupilumab Injection Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 54. Asia-Pacific Dupilumab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 55. Asia-Pacific Dupilumab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 56. Indonesia Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 57. Japan Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 58. South Korea Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 59. China Taiwan Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 60. India Dupilumab Injection Revenue (2020-2031) & (US$ Million)
Figure 61. Central and South America Dupilumab Injection Sales YoY (2020-2031) & (K Units)
Figure 62. Central and South America Dupilumab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Central and South America Top 5 Manufacturers Dupilumab Injection Sales Revenue (US$ Million) in 2024
Figure 64. Central and South America Dupilumab Injection Sales Volume (K Units) by Type (2021-2031)
Figure 65. Central and South America Dupilumab Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 66. Central and South America Dupilumab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 67. Central and South America Dupilumab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 68. Brazil Dupilumab Injection Revenue (2020-2025) & (US$ Million)
Figure 69. Argentina Dupilumab Injection Revenue (2020-2025) & (US$ Million)
Figure 70. Middle East, and Africa Dupilumab Injection Sales YoY (2020-2031) & (K Units)
Figure 71. Middle East and Africa Dupilumab Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 72. Middle East and Africa Top 5 Manufacturers Dupilumab Injection Sales Revenue (US$ Million) in 2024
Figure 73. Middle East and Africa Dupilumab Injection Sales Volume (K Units) by Type (2021-2031)
Figure 74. South America Dupilumab Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 75. Middle East and Africa Dupilumab Injection Sales Volume (K Units) by Application (2020-2031)
Figure 76. Middle East and Africa Dupilumab Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 77. GCC Countries Dupilumab Injection Revenue (2020-2025) & (US$ Million)
Figure 78. Turkey Dupilumab Injection Revenue (2020-2025) & (US$ Million)
Figure 79. Egypt Dupilumab Injection Revenue (2020-2025) & (US$ Million)
Figure 80. South Africa Dupilumab Injection Revenue (2020-2025) & (US$ Million)
Figure 81. Dupilumab Injection Industry Chain Mapping
Figure 82. Regional Dupilumab Injection Manufacturing Base Distribution (%)
Figure 83. Global Dupilumab Injection Production Market Share by Region (2020-2031)
Figure 84. Dupilumab Injection Production Process
Figure 85. Regional Dupilumab Injection Production Cost Structure
Figure 86. Channels of Distribution (Direct Vs Distribution)
Figure 87. Bottom-up and Top-down Approaches for This Report
Figure 88. Data Triangulation
Figure 89. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global UV Delayed Curing Adhesives Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Die-Casting Die Steel Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Adaptive Neuromodulation Therapy Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232